| Aug 5 |
FibroGen Q2 2024 Earnings Preview
|
| Jul 31 |
FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials
|
| Jul 31 |
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
|
| Jul 31 |
Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
|
| Jul 30 |
FibroGen stock plunges 48% post-market on failed drug studies
|
| Jul 30 |
FibroGen to Report Second Quarter 2024 Financial Results
|
| Jul 30 |
FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update
|
| Jul 29 |
FibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%
|
| Jun 28 |
FibroGen files for $300M mixed shelf offering
|
| Jun 18 |
Favourable Signals For FibroGen: Numerous Insiders Acquired Stock
|
